C反应蛋白与前白蛋白的比率（CPAR）已被提出并引入胃肠道癌症治疗中。本研究旨在评估 CPAR 对接受根治性治疗的胃癌 (GC) 患者的临床影响。本研究纳入了 2013 年至 2017 年间接受根治性治疗的 447 例 GC 患者。比较了以下患者的预后和临床病理参数：高和低 CPAR。使用对数秩检验比较按每个临床因素分层的总生存期 (OS)，使用 5.0 的治疗前 CPAR 观察到显着差异。 CPAR 低（CPAR <5.0）组和 CPAR 高（CPAR ≥5.0）组的 3 年和 5 年 OS 率存在显着差异。 CPAR 低组的 3 年和 5 年 OS 率分别为 92.6% 和 87.8%，CPAR 高组为 88.0% 和 75.4%。在多变量分析中，CPAR 被确定为 OS 的重要预后因素 (p=0.032)。无复发生存期也观察到类似的结果。CAPR 是 GC 患者的预后因素。因此，CAPR 可能是一种有前景的炎症营养生物标志物，可应用于 GC 患者的管理。版权所有 © 2023 国际抗癌研究所（George J. Delinasios 博士），保留所有权利。

The C-reactive protein to prealbumin ratio (CPAR) has been proposed and introduced in gastrointestinal cancer management. This study aimed to evaluate the clinical impact of the CPAR in patients with gastric cancer (GC) who received curative treatment.This study included 447 patients who underwent curative treatment for GC between 2013 and 2017. The prognosis and clinicopathological parameters were compared between patients with high and low CPARs.Overall survival (OS) stratified by each clinical factor was compared using the log-rank test, and a significant difference was observed using a pretreatment CPAR of 5.0. Significant differences were observed in the 3- and 5-year OS rates of the CPAR-low (CPAR <5.0) and CPAR-high (CPAR ≥5.0) groups. The 3- and 5-year OS rates were 92.6% and 87.8%, respectively, in the CPAR-low group and 88.0% and 75.4% in the CPAR-high group. The CPAR was determined to be a significant prognostic factor for OS in a multivariate analysis (p=0.032). Similar results were observed for recurrence-free survival.The CAPR is a prognostic factor for GC patients. Therefore, the CAPR may be a promising nutritional biomarker of inflammation that can be applied in the management of GC patients.Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.